Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest Articles30 years of dynorphins — New insights on their functions in neuropsychiatric diseases
Pharmacology & Therapeutics, 09/14/09
Schwarzer C – Discrepancies between the distribution of opioid receptor binding sites and dynorphin immunoreactivity contributed to the difficulties in interpretation. In recent years, the generation of prodynorphin– and opioid receptor–deficient mice has provided the tools to investigate open questions on network effects of endogenous dynorphins.
Related Articles
TREX1 Gene Variant in Neuropsychiatric Systemic Lupus Erythematosus
Annals of Rheumatic Diseases, 11/11/09
Relevance Score: 85%
Clinical implications of neuropsychiatric systemic lupus erythematosus
Advances in Psychiatric Treatment, 11/04/09
Relevance Score: 84%
Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations
Expert Review of Neurotherapeutics, 10/08/09
Relevance Score: 84%
Neuropsychiatric Systemic Lupus Erythematosus Presenting as Bipolar I Disorder With Catatonic Features
Psychosomatics, 10/29/09
Relevance Score: 83%
Retinal Response to Light in Young Nonaffected Offspring at High Genetic Risk of Neuropsychiatric Brain Disorders
Biological Psychiatry, 10/23/09
Relevance Score: 83%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/07/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/07/09
Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease
Bayer HealthCare Pharmaceuticals, 12/07/09
Sponsor
Article Search
Sponsor